Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita | Aplastic Anemia & MDS International Foundation
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

Clinical Trial: NCT01659606

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:

Dyskeratosis congenita (DC) is an inherited multisystem disorder, which classically presents with a clinical triad of skin pigment abnormalities, nail dystrophy, and oral leukoplakia. DC is part of a spectrum of telomere biology disorders, which include some forms of inherited idiopathic aplastic anemia, myelodysplastic syndrome, and pulmonary fibrosis and the congenital diseases Hoyeraal-Hreidarsson syndrome and Revesz syndrome. Progressive bone marrow failure (BMF) occurs in more than 80% of patients under 30 years of age and is the primary cause of morbidity and mortality, followed by pulmonary failure and malignancies. Allogeneic hematopoietic cell transplantation (HCT) is curative for the hematological defects, but several studies have demonstrated poor outcomes in DC patients due to increased early and late complications. A predisposition to pulmonary failure, vascular disease and secondary malignancies may contribute to the high incidence of fatal complications following HCT in DC patients, and provides an impetus to reduce exposure to chemotherapy and radiotherapy in preparative regimens. Recent studies suggest that fludarabine-based conditioning regimens provide stable engraftment and may avoid the toxicities seen after HCT for DC, but studies to date are limited to case reports, retrospective studies and a single prospective trial. In this study, we propose to prospectively evaluate the efficacy of a fludarabine- and antibody-based conditioning regimen in HCT for DC patients, with the goals of maintaining donor hematopoiesis and transfusion independence while decreasing early and late complications of HCT for DC.

Study Date: 
Mon, 08/06/2012 to Sun, 10/01/2017
Bone Marrow Disease(s): 
aplastic anemia
Biological: alemtuzumab Conditioning: alemtuzumab 0.2 mg/kg/dose IV x 5 doses Other Name: Campath-1H Drug: Fludarabine fludarabine 30 mg/m2/dose IV x 6 doses Other Name: Fludara Drug: Cyclosporins Starting Day -2 beginning at 1.5 mg/kg IV twice per day, infused over 2 hours, titrated to maintain a serum trough level of 150 -200 ng/ml. CSA will be administered for a minimum of 6 months and then tapered over 10 weeks. Other Names: cyclosporine A Neoral Sandimmune Drug: Mycophenolate mofetil 15 mg/kg IV three times a day from day 0 to day +53 Other Name: Cellcept